A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours

Immune checkpoint inhibitors have been approved in the USA for tumours exhibiting mismatch repair deficiency (dMMR), microsatellite instability (MSI), or high tumour mutational burden (TMB), with regulatory and reimbursement applications in multiple other countries underway. As the estimated budget...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Yoon-Jung, O’Haire, Sophie, Franchini, Fanny, IJzerman, Maarten, Zalcberg, John, Macrae, Finlay, Canfell, Karen, Steinberg, Julia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705554/
https://www.ncbi.nlm.nih.gov/pubmed/36443366
http://dx.doi.org/10.1038/s41598-022-23319-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705554/
https://www.ncbi.nlm.nih.gov/pubmed/36443366
http://dx.doi.org/10.1038/s41598-022-23319-1

Ejemplares similares